氟代脱氧葡萄糖（F18-AV-45）正电子发射断层扫描（PET）评估阿尔茨海默病痴呆、轻度认知障碍和正常老化的淀粉样蛋白负担。
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.
机构信息
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
出版信息
Alzheimers Dement. 2013 Oct;9(5 Suppl):S72-83. doi: 10.1016/j.jalz.2012.10.007. Epub 2013 Jan 30.
Abstract
OBJECTIVE
To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs).
METHODS
Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative.
RESULTS
Florbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty-four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status.
CONCLUSIONS
: The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.
摘要
目的
评估氟代脱氧葡萄糖 F18 正电子发射断层扫描（PET）在阿尔茨海默病（AD）、轻度认知障碍（MCI）和健康对照受试者（HCs）中的性能特征。
方法
在一项多中心 2 期研究中，184 名受试者（45 名 AD 患者、60 名 MCI 患者和 79 名 HCs）接受了氟代脱氧葡萄糖 PET 扫描。淀粉样蛋白负担通过视觉和定量评估进行评估，并分为阳性或阴性。
结果
氟代脱氧葡萄糖 PET 视觉评分显示，76%的 AD 患者、38%的 MCI 患者和 14%的 HCs 存在淀粉样蛋白阳性。使用定量阈值，84%的 AD 患者、45%的 MCI 患者和 23%的 HCs 被分类为淀粉样蛋白阳性。淀粉样蛋白阳性和平均皮质淀粉样蛋白负荷与年龄和载脂蛋白 E ε4 携带状态相关。
结论
这些数据与 AD 和 MCI 临床诊断个体中预期的淀粉样蛋白阳性率一致，表明氟代脱氧葡萄糖 F18 PET 作为临床诊断辅助手段具有潜在价值。
相似文献
1
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.氟代脱氧葡萄糖（F18-AV-45）正电子发射断层扫描（PET）评估阿尔茨海默病痴呆、轻度认知障碍和正常老化的淀粉样蛋白负担。
Alzheimers Dement. 2013 Oct;9(5 Suppl):S72-83. doi: 10.1016/j.jalz.2012.10.007. Epub 2013 Jan 30.
2
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.载脂蛋白 E ε4 及年龄对健康衰老和阿尔茨海默病中氟比他滨正电子发射断层扫描的影响。
Neurobiol Aging. 2013 Jan;34(1):1-12. doi: 10.1016/j.neurobiolaging.2012.04.017. Epub 2012 May 24.
3
Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.氟代硼吡咯（¹⁸F）在日本健康志愿者、轻度认知障碍患者及阿尔茨海默病患者中的成像特征与安全性
Ann Nucl Med. 2015 Aug;29(7):570-81. doi: 10.1007/s12149-015-0978-2. Epub 2015 May 6.
4
Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.双相（18）F-氟代硼吡咯（AV-45/Amyvid）PET在阿尔茨海默病和轻度认知障碍中同时检测灌注缺损和β-淀粉样蛋白沉积的成像特征
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1304-14. doi: 10.1007/s00259-016-3359-8. Epub 2016 Mar 22.
5
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.使用正电子发射断层扫描和氟代硼吡咯 F18 对轻度认知障碍或阿尔茨海默病所致痴呆患者的皮质淀粉样蛋白进行成像。
Arch Neurol. 2011 Nov;68(11):1404-11. doi: 10.1001/archneurol.2011.150. Epub 2011 Jul 11.
6
18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.18F-FDG 在阿尔茨海默病和轻度认知障碍评估中比 18F-氟比他滨更能准确反映认知表现：一项全球定量分析。
J Alzheimers Dis. 2019;70(4):1197-1207. doi: 10.3233/JAD-190220.
7
Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.不同亚型轻度认知障碍的重度抑郁症患者的β-淀粉样蛋白沉积与认知功能：（18）F-氟代硼吡咯（AV-45/amyvid）PET研究
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1067-76. doi: 10.1007/s00259-015-3291-3. Epub 2016 Jan 7.
8
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.氟替卡匹尔PET tau蛋白结合与淀粉样蛋白负荷、临床诊断、年龄和认知之间的关系。
Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.
9
Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth.绘制 ApoE4、年龄和认知状态对 18F-氟比他哌 PET 测量的β-淀粉样蛋白密度和生长的区域性皮质模式的影响。
Neuroimage. 2013 Sep;78:474-80. doi: 10.1016/j.neuroimage.2013.04.048. Epub 2013 Apr 23.
10
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代硼吡咯进行18F正电子发射断层显像以早期诊断轻度认知障碍（MCI）患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
引用本文的文献
1
Motion correction of simultaneous brain PET/MR images based on tracer uptake characteristics.基于示踪剂摄取特征的同步脑PET/MR图像运动校正
EJNMMI Phys. 2025 Jul 30;12(1):75. doi: 10.1186/s40658-025-00789-6.
2
Case study of a 47-year-old long COVID patient diagnosed with Alzheimer's disease.一名47岁的长期新冠患者被诊断出患有阿尔茨海默病的病例研究。
Quant Imaging Med Surg. 2025 Jul 1;15(7):6535-6540. doi: 10.21037/qims-2025-125. Epub 2025 Jun 30.
3
Potential utility of salivary gland amyloid uptake as a surrogate marker for adipose tissue and amyloid-beta dynamics based on its association with BMI and cerebral amyloid burden.基于唾液腺淀粉样蛋白摄取与体重指数及脑淀粉样蛋白负荷的关联，其作为脂肪组织和β淀粉样蛋白动态变化替代标志物的潜在效用。
Sci Rep. 2025 Jul 15;15(1):25513. doi: 10.1038/s41598-025-11731-2.
4
Machine learning model for predicting Amyloid-β positivity and cognitive status using early-phase F-Florbetaben PET and clinical features.使用早期¹⁸F-氟贝他班PET和临床特征预测β淀粉样蛋白阳性和认知状态的机器学习模型
Sci Rep. 2025 Jul 1;15(1):21987. doi: 10.1038/s41598-025-00743-7.
5
Auto-branch multi-task learning for simultaneous prediction of multiple correlated traits associated with Alzheimer's disease.用于同时预测与阿尔茨海默病相关的多个相关性状的自动分支多任务学习
Front Genet. 2025 Jun 10;16:1538544. doi: 10.3389/fgene.2025.1538544. eCollection 2025.
6
Unraveling Alzheimer's complexity with a distinct Aβ fibril type and specific AV-45 binding.通过独特的Aβ纤维类型和特定的AV-45结合来揭示阿尔茨海默病的复杂性。
Nat Chem Biol. 2025 Jun 10. doi: 10.1038/s41589-025-01921-4.
7
Deep-learning based multi-modal models for brain age, cognition and amyloid pathology prediction.基于深度学习的脑龄、认知和淀粉样蛋白病理学预测多模态模型。
Alzheimers Res Ther. 2025 May 31;17(1):126. doi: 10.1186/s13195-025-01773-z.
8
Localization of Network-Level Atrophy in Preclinical Alzheimer's Disease.临床前阿尔茨海默病中网络水平萎缩的定位
Res Sq. 2025 May 5:rs.3.rs-5977523. doi: 10.21203/rs.3.rs-5977523/v1.
9
Evaluation of early-phase F-Florbetaben PET as a surrogate biomarker of neurodegeneration: In-depth comparison with F-FDG PET at group and single patient level.早期F-氟代硼替苯正电子发射断层扫描（PET）作为神经退行性变替代生物标志物的评估：在组水平和单患者水平与F-氟代脱氧葡萄糖PET的深入比较
J Alzheimers Dis. 2025 Jul;106(1):304-316. doi: 10.1177/13872877251340380. Epub 2025 May 8.
10
Establishing Regional Aβ Cutoffs and Exploring Subgroup Prevalence Across Cognitive Stages Using BeauBrain Amylo.利用BeauBrain淀粉样蛋白确定区域Aβ临界值并探索认知阶段亚组患病率。
Dement Neurocogn Disord. 2025 Apr;24(2):135-146. doi: 10.12779/dnd.2025.24.2.135. Epub 2025 Apr 9.
本文引用的文献
1
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.阿尔茨海默病患者和认知正常受试者中氟[18F]氟比他滨 F 18 淀粉样蛋白 PET 的性能特征。
J Nucl Med. 2012 Mar;53(3):378-84. doi: 10.2967/jnumed.111.090340. Epub 2012 Feb 13.
2
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.阿尔茨海默病所致痴呆的诊断：美国国家老龄化研究所-阿尔茨海默病协会工作组关于阿尔茨海默病诊断指南的建议。
Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.
3
Amyloid-β associated cortical thinning in clinically normal elderly.临床正常老年人中与淀粉样蛋白-β相关的皮质变薄。
Ann Neurol. 2011 Jun;69(6):1032-42. doi: 10.1002/ana.22333. Epub 2011 Mar 17.
4
Use of florbetapir-PET for imaging beta-amyloid pathology.氟代脱氧葡萄糖-PET 用于成像β淀粉样蛋白病理。
JAMA. 2011 Jan 19;305(3):275-83. doi: 10.1001/jama.2010.2008.
5
Revising the definition of Alzheimer's disease: a new lexicon.修订阿尔茨海默病的定义：一个新词汇。
Lancet Neurol. 2010 Nov;9(11):1118-27. doi: 10.1016/S1474-4422(10)70223-4. Epub 2010 Oct 9.
6
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).使用放射性配体 18F-AV-45（florbetapir [校正] F 18）对阿尔茨海默病中的淀粉样蛋白沉积进行体内成像。
J Nucl Med. 2010 Jun;51(6):913-20. doi: 10.2967/jnumed.109.069088.
7
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.澳大利亚老龄化影像、生物标志物与生活方式（AIBL）研究的淀粉样蛋白成像结果。
Neurobiol Aging. 2010 Aug;31(8):1275-83. doi: 10.1016/j.neurobiolaging.2010.04.007. Epub 2010 May 15.
8
Cognition, reserve, and amyloid deposition in normal aging.正常衰老过程中的认知、储备和淀粉样蛋白沉积。
Ann Neurol. 2010 Mar;67(3):353-64. doi: 10.1002/ana.21904.
9
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.11C-PiB PET 评估 bapineuzumab 治疗阿尔茨海默病患者纤维状淀粉样β负荷的变化：一项 2 期、双盲、安慰剂对照、递增剂量研究。
Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.
10
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.18F-AV-45的临床前特性：一种用于检测大脑中β淀粉样蛋白斑块的正电子发射断层显像（PET）剂
J Nucl Med. 2009 Nov;50(11):1887-94. doi: 10.2967/jnumed.109.065284. Epub 2009 Oct 16.
Zotero 插件